Alpa Laboratories Ltd

Wed 16/09/2026,15:53:15 | NSE : ALPA

₹61.120.73 (1.21%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 60.06

Previous Close

₹ 60.39

Volume

14768

Mkt Cap ( ₹ Cr)

₹ 128.60

High

₹ 64.50

Low

₹ 59.40

52 Week High

₹ 96.80

52 Week Low

₹ 46.10

Book Value Per Share

₹ 89.00

Dividend Yield

0.00

Face Value

₹ 10.00

What's Your Call?

Collective community sentiment on Alpa Laboratories Ltd

Your Vote -

Buy

68.75%

Hold

12.50%

Sell

18.75%

68.75%

32 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

NaN%

Sell Order Quantity

NaN%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Alpa Laboratories Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Alpa Laboratories - Reg. 34 (1) Annual Report.

    7 Sep 2026, 9:41PM Annual Report for the Financial Year Ended March 31,2026
  • Alpa Laboratories - Record Date

    7 Sep 2026, 3:52PM Alpa Laboratories Limited has informed the Exchange that Record date for the purpose of Meeting is 22-Sep-2026.
  • Alpa Laboratories - Appointment

    7 Sep 2026, 3:13PM Alpa Laboratories Limited has informed the Exchange regarding Appointment of Mrs RADHIKA as Non- Execut of the company w.e.f. September 05, 2026.
  • Alpa Laboratories - Fixes Book Closure For The Purpose Of AGM.

    7 Sep 2026, 3:46PM Intimation of Book Closure for the Purpose of 38th AGM.
  • Alpa Laboratories - Announcement under Regulation 30 (LODR)-Change in Management

    7 Sep 2026, 2:13PM Appointment of Mrs. Radhika Biyani as an Independent Director.
  • Alpa Laboratories - Outcome of Board Meeting

    13 Aug 2026, 9:07PM Alpa Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
  • Alpa Laboratories - Results For The Quarter Ended June 2026

    13 Aug 2026, 8:30PM Results for the quarter ended June 2026 along with the approval of Notice of 38th Annual General Meeting
  • Alpa Laboratories - Updates

    11 Aug 2026, 6:02PM Alpa Laboratories Limited has informed the Exchange regarding 'clarification board meeting date'.
  • Alpa Laboratories - CLARIFICATION ON BOARD MEETING

    11 Aug 2026, 5:58PM CLARIFICATION ON BOARD MEETING DATE WITH RESPECT TO THE EARLIER SUBMISSION
  • Alpa Laboratories - Board Meeting Intimation for Approval Of The Standalone And Consolidated Unaudited Financial Results For

    4 Aug 2026, 4:45PM Alpa Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider an
  • Alpa Laboratories - General Updates

    29 Jul 2026, 6:16PM Alpa Laboratories Limited has informed the Exchange about General Updates
  • Alpa Laboratories - Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, For Materi

    29 Jul 2026, 6:10PM Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
  • Alpa Laboratories - Reply to Clarification- Financial results

    27 Jul 2026, 1:28PM The Exchange had sought clarification from Alpa Laboratories Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (List
  • Alpa Laboratories - Cessation

    22 Jul 2026, 3:55PM Alpa Laboratories Limited has informed the Exchange regarding Cessation of Ms.Jyoti Jain as Non- Executive Independent Director of the company w.e.f.
  • Alpa Laboratories - Announcement under Regulation 30 (LODR)-Cessation

    22 Jul 2026, 3:45PM Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 , we hereby inform you that
  • Alpa Laboratories has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    15 Jul 2026, 3:30PM As of June 2026, 57.19% is owned by Indian Promoters and 42.81% by Public. <p align=justify> Top five Promoters holding highest number of shares of Al
  • Alpa Laboratories - Cessation

    8 Jul 2026, 4:45PM Alpa Laboratories Limited has informed the Exchange regarding Cessation of Ms Yashoda Patidar as Company Secretary & Compliance Officer of the compan
  • Alpa Laboratories - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer

    8 Jul 2026, 4:36PM Ms.Yashoda Patidar has resigned from the post of Company Secretary & Complaince Officer w.e.f. 26th July 2026.
  • Alpa Laboratories - Trading Window

    25 Jun 2026, 2:18PM Alpa Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations
  • Alpa Laboratories - Clarification - Financial Results

    25 Jun 2026, 11:00AM The Exchange has sought clarification from Alpa Laboratories Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (List
  • Alpa Laboratories - Disclosure under SEBI Takeover Regulations

    19 Jun 2026, 3:09PM Alpa Laboratories Limitedÿhas Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Sub

Key fundamentals

Evaluate the intrinsic value of Alpa Laboratories Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 198.0879 181.8358 167.2191 147.1215 137.4871
Liabilities 198.0879 181.8358 167.2191 147.1215 137.4871
Equity 21.0406 21.0406 21.0406 21.0406 21.0406
Gross Profit 3.3039 5.0047 8.1447 8.0761 10.6864
Net Profit 14.9531 19.6794 16.7777 12.6243 14.1258
Cash From Operating Activities 11.484 18.3945 3.6991 8.8196 2.2041
NPM(%) 14.13 17.5 15.42 13.58 12.58
Revenue 105.8096 112.4519 108.7391 92.9552 112.2664
Expenses 102.5057 107.4472 100.5944 84.8791 101.58
ROE(%) 7.98 10.5 8.95 6.74 7.54

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Alpa Laboratories Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 860.45 1.00 21.76 33.97 -26.19 0.58
Lotus Eye Hospital and Institute Ltd 114.94 3.93 1642.00 123.80 0.39 0.00
Vaishali Pharma Ltd 8.68 -3.77 27.13 776.64 15.42 0.00
Astec Lifesciences Ltd 661.95 -1.74 0.00 132.65 -363.14 0.00

Company Info

Mr. Purushottam R. Patel, Mr. M.S. Chawla and Mr. Pravin C. Shah, partners of M/s Alpa Laboratories, which was formed in the year 1967, incorporated a private limited company in the name of Alpa Laboratories Private Limited on March 18, 1988 for manufacture of pharmaceutical formulations. In the year 1998, Alpa Laboratories Private Limited was converted into a public limited company with effect from September 3, 1998 with the name of "Alpa Laboratories Limited". In the year 1997, we initiated setting of a new manufacturing unit at 33/2, Pigdamber, A.B. Road, Rau, District Indore, Madhya Pradesh. The unit commenced commercial production in the year 1999 of all types of formulations viz. Injectables (Vials/Ampoules both liquid and Dry), tablets, capsules, eye/ear drops, ointment and creams. We manufacture a range of products such as ethical drugs, generic drugs, over the counter drugs (OTC) and veterinary products in various dosage forms and market them under the trade mark "Alpa" which is a registered trademark in the name of Alpa Labs (India) Limited, a promoter group company. We also manufacture formulations for a number of other pharmaceutical companies of national and international repute such as Cipla, Zydus Cadila, Lupin, Glenmark, Genom Biotech, Jenburkt, etc. (under their own brands) located both in India and abroad in countries such as Philippines, Iran, Iraq, Sierra Leon, Madagascar, Kenya, Liberia, Puerto Rico, Haiti, Sudan, Ghana, Nigeria, Srilanka etc. Further, we also undertake contract manufacturing of a large variety of pharmaceuticals. We manufacture various dosage forms which include injectables (vials / ampoules both liquid and dry), tablets, capsules, eye / ear drops, ointment and creams and dry syrups. We have an established product-marketing network covering both metro and mini metro cities, which enable us to reach our existing and potential customers through our network of distributors and dealers spread across the country. For the purpose of marketing the various products, our Company's business has been categorized as Branded Generic Division, Veterinary Division, Exports Division and Contract Manufacturing Division. HISTORY AND MAJOR EVENTS 1988 Incorporation of Alpa Laboratories Private Limited 1997 Commenced setting up of manufacturing facility at Pigdamber, Indore 1998 Conversion to Alpa Laboratories Limited, a public limited company 1999 Start of commercial production 2001 WHO GMP Certification for its manufacturing facilities Entered into an agreement for Contract manufacturing at its newly constructed facility, with Plethico Pharmaceuticals Ltd., a Pharmaceutical company, for manufacturing its various range of products. The manufacturing facilities at Pigdamber were certified as WHO GMP compliant by SGS-ICS Belgium for the period 2001-02. 2003 Certified ISO 9001: 2000* The manufacturing facility at Pigdamber was approved by the Director General of Quality Assurance (DGQA), India thereby opening its doors for participating in Tenders for supplies to defence institutions** Started export of its Veterinary products and registered its 7 veterinary products in Sudan 2006 Started participation in international tenders for export in addition to domestic marketing abroad and won a major tender from CMS, Sudan. Launched Veterinary Division with a new face and ethical promotion of its Veterinary products launched in 5 states in the year 2006. Launched Ethical division for its human products * Expired on May 14, 2006 ** Expired on January 22, 2006. This certificate is not required now as our revenue have crossed Rs 2000.00 lakhs as per DGQA norms. 2007 -Alpa Laboratories ties up with Vhermann Pharmaceutical Inc, Philippines for distribution of its products. 2010 - The Company has recommended dividend of 10%. 2014 - Ms. Monali Patel, Member of The Institute of Company Secretaries of India (ICSI) has been appointed as the Company Secretary and Compliance Officer. - Alpa Laboratories has sold its Unit-II ("Undertaking) situated at Sector III, Pithampur, Dhar (M.P.) as a going concern on a slump sale basis to Ipca Laboratories Limited. 2015 -Alpa Laboratories Ltd has formed a wholly owned subsidiary under the name and style of Norfolk Mercantile Private Ltd.

Mr. Purushottam R. Patel, Mr. M.S. Chawla and Mr. Pravin C. Shah, partners of M/s Alpa Laboratories, which was formed in the year 1967, incorporated a private limited company in the name of Alpa Laboratories Private Limited on March 18, 1988 for manufacture of pharmaceutical formulations. In the year 1998, Alpa Laboratories Private Limited was converted into a public limited company with effect from September 3, 1998 with the name of "Alpa Laboratories Limited". In the year 1997, we initiated setting of a new manufacturing unit at 33/2, Pigdamber, A.B. Road, Rau, District Indore, Madhya Pradesh. The unit commenced commercial production in the year 1999 of all types of formulations viz. Injectables (Vials/Ampoules both liquid and Dry), tablets, capsules, eye/ear drops, ointment and creams. We manufacture a range of products such as ethical drugs, generic drugs, over the counter drugs (OTC) and veterinary products in various dosage forms and market them under the trade mark "Alpa" which is a registered trademark in the name of Alpa Labs (India) Limited, a promoter group company. We also manufacture formulations for a number of other pharmaceutical companies of national and international repute such as Cipla, Zydus Cadila, Lupin, Glenmark, Genom Biotech, Jenburkt, etc. (under their own brands) located both in India and abroad in countries such as Philippines, Iran, Iraq, Sierra Leon, Madagascar, Kenya, Liberia, Puerto Rico, Haiti, Sudan, Ghana, Nigeria, Srilanka etc. Further, we also undertake contract manufacturing of a large variety of pharmaceuticals. We manufacture various dosage forms which include injectables (vials / ampoules both liquid and dry), tablets, capsules, eye / ear drops, ointment and creams and dry syrups. We have an established product-marketing network covering both metro and mini metro cities, which enable us to reach our existing and potential customers through our network of distributors and dealers spread across the country. For the purpose of marketing the various products, our Company's business has been categorized as Branded Generic Division, Veterinary Division, Exports Division and Contract Manufacturing Division. HISTORY AND MAJOR EVENTS 1988 Incorporation of Alpa Laboratories Private Limited 1997 Commenced setting up of manufacturing facility at Pigdamber, Indore 1998 Conversion to Alpa Laboratories Limited, a public limited company 1999 Start of commercial production 2001 WHO GMP Certification for its manufacturing facilities Entered into an agreement for Contract manufacturing at its newly constructed facility, with Plethico Pharmaceuticals Ltd., a Pharmaceutical company, for manufacturing its various range of products. The manufacturing facilities at Pigdamber were certified as WHO GMP compliant by SGS-ICS Belgium for the period 2001-02. 2003 Certified ISO 9001: 2000* The manufacturing facility at Pigdamber was approved by the Director General of Quality Assurance (DGQA), India thereby opening its doors for participating in Tenders for supplies to defence institutions** Started export of its Veterinary products and registered its 7 veterinary products in Sudan 2006 Started participation in international tenders for export in addition to domestic marketing abroad and won a major tender from CMS, Sudan. Launched Veterinary Division with a new face and ethical promotion of its Veterinary products launched in 5 states in the year 2006. Launched Ethical division for its human products * Expired on May 14, 2006 ** Expired on January 22, 2006. This certificate is not required now as our revenue have crossed Rs 2000.00 lakhs as per DGQA norms. 2007 -Alpa Laboratories ties up with Vhermann Pharmaceutical Inc, Philippines for distribution of its products. 2010 - The Company has recommended dividend of 10%. 2014 - Ms. Monali Patel, Member of The Institute of Company Secretaries of India (ICSI) has been appointed as the Company Secretary and Compliance Officer. - Alpa Laboratories has sold its Unit-II ("Undertaking) situated at Sector III, Pithampur, Dhar (M.P.) as a going concern on a slump sale basis to Ipca Laboratories Limited. 2015 -Alpa Laboratories Ltd has formed a wholly owned subsidiary under the name and style of Norfolk Mercantile Private Ltd.

Parent Organisation

Alpa Laboratories Ltd.

Founded

18/03/1988

Managing Director

Mr.Paresh Chawla

NSE Symbol

ALPAEQ

FAQ